Phytopharm

Phytopharm is a development stage pharmaceutical company developing novel treatments targeting diseases with high levels of unmet need. Our lead series of compounds, the Sapogenins (including Cogane™ and Myogane™), has the potential to be a new class of therapy for neurodegenerative diseases including Parkinson’s disease, ALS and glaucoma.

Phytopharm’s strategic direction has evolved from developing products extracted from natural botanical sources to investigating single chemical entities.

Phytopharm operates as a virtual company. We utilise a network of scientific and clinical experts to help guide our development projects with our experienced pharmaceutical managers overseeing operations.

Phytopharm is listed on the London Stock Exchange main list (LSE: PYM).
Type: NORMAL
Address: Lakeview House 2 Lakeview Court Ermine Business Park Huntingdon PE29 6UA
Website: http://www.phytopharm.com
Phone: +44 (0)1480 437697
Fax: +44 (0)1480 417090
Email: :info@phytopharm.com
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.